| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 27.2 | 30.1 | 38.2 |
| Other income | 1.0 | 0.1 | 0.4 |
| Total income | 28.2 | 30.2 | 38.7 |
| Profit before exceptional items & tax | 1.8 | 5.1 | 6.3 |
| Profit before tax | 1.8 | 5.1 | 6.3 |
| Net profit | 0.4 | 5.4 | 2.0 |
| Operating margin | 6.4% | 16.9% | 16.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -80.00% |
|---|---|
| Net profit, quarter on quarter | -92.60% |
| Revenue, year on year | -28.80% |
BSE results filing, NSE: LAURLOR. Figures extracted from the filing.
Kimia Biosciences Ltd: key numbers
- Share price
- ₹30.77
- Market cap
- ₹145.6 Cr
- Revenue (annual)
- ₹114.9 Cr
- Net profit (annual)
- ₹7.43 Cr
- P/E (TTM)
- 20.3×Sector 50.4×
- Promoter holding
- 74.94%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kimia Biosciences Ltd
All →Kimia Biosciences Other Announcement
The company filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ended March 31, 2026.
Kimia Biosciences Annual General Meeting
Kimia Biosciences Limited has submitted its notice for the 33rd Annual General Meeting scheduled for September 28, 2026, along with the Annual Report for FY 2025-26.
Kimia Biosciences Board Meeting Outcome
Kimia Biosciences' board meeting outcome includes director appointments, approval of the 33rd AGM notice, and increased borrowing/investment limits. The board also adopted the annual report.
Kimia Biosciences Q1 FY27 Results: Net Profit ₹0.4 Cr, Down 33.3% YoY
Kimia Biosciences Ltd reported revenue from operations of ₹20.7 Cr (-12.3% YoY) and net profit of ₹0.4 Cr (-33.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.4 Cr · -33.3% YoY